Tejas Patil

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9283023/publications.pdf

Version: 2024-02-01

57 papers	1,469 citations	687363 13 h-index	345221 36 g-index
59 all docs	59 docs citations	59 times ranked	1806 citing authors

#	Article	IF	Citations
1	Acquired Resistance to KRAS^{G12C} Inhibition in Cancer. New England Journal of Medicine, 2021, 384, 2382-2393.	27.0	482
2	Management of Brain Metastases in Tyrosine Kinase Inhibitorâ€“NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372
3	The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Nonâ€“Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, 1717-1726.	1.1	119
4	Predictive value of oncogenic driver subtype, programmed deathâ€1 ligand (PDâ€L1) score, and smoking status on the efficacy of PDâ€1/PDâ€L1 inhibitors in patients with oncogeneâ€driven nonâ€“small cell lung cancer. Cancer, 2019, 125, 1038-1049.	4.1	66
5	ROS1 Gene Rearrangements Are Associated With an Elevated Risk of Peridiagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2019, 14, 596-605.	1.1	56
6	Brain Metastases in EGFR- and ALK-Positive NSCLC: Outcomes of Central Nervous System-Penetrant Tyrosine Kinase Inhibitors Alone Versus in Combination With Radiation. Journal of Thoracic Oncology, 2022, 17, 116-129.	1.1	50
7	On the ontological assumptions of the medical model of psychiatry: philosophical considerations and pragmatic tasks. Philosophy, Ethics, and Humanities in Medicine, 2010, 5, 3.	1.5	38
8	Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2020, 21, e191-e204.	2.6	26
9	A tyrosine kinase inhibitor-induced interferon response positively associates with clinical response in EGFR-mutant lung cancer. Npj Precision Oncology, 2021, 5, 41.	5.4	22
10	Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. Journal of Thoracic Oncology, 2018, 13, 134-138.	1.1	21
11	Malignant pleural disease is highly associated with subsequent peritoneal metastasis in patients with stage IV non-small cell lung cancer independent of oncogene status. Lung Cancer, 2016, 96, 27-32.	2.0	20
12	Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. Oncologist, 2022, , .	3.7	18
13	2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist, 2021, 26, e454-e472.	3.7	17
14	Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs of Today, 2019, 55, 641.	1.1	16
15	Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusionâ€“Positive NSCLC. JTO Clinical and Research Reports, 2022, 3, 100332.	1.1	15
16	Detection of oligoprogressive disease in oncogene-addicted non-small cell lung cancer using PET/CT versus CT in patients receiving a tyrosine kinase inhibitor. Lung Cancer, 2018, 126, 112-118.	2.0	14
17	Duration of Targeted Therapy in Patients With Advanced Nonâ€“small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis. Clinical Lung Cancer, 2020, 21, 545-552.e1.	2.6	11
18	Central Nervous System Response to Selpercartinib in Patient With RET-rearranged Non-small Cell Lung Cancer After Developing Leptomeningeal Disease on Pralsetinib. Clinical Lung Cancer, 2022, 23, e5-e8.	2.6	11

#	Article	IF	Citations
19	Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers. JTO Clinical and Research Reports, 2021, 2, 100187.	1.1	11
20	NRG1 fusion-positive lung cancers: Clinicopathologic profile and treatment outcomes from a global multicenter registry.. Journal of Clinical Oncology, 2019, 37, 9081-9081.	1.6	11
21	Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer. Lung Cancer, 2017, 109, 28-35.	2.0	10
22	Miliary Metastases in Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2018, 379, 1945-1945.	27.0	8
23	Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer. , 2021, , .		8
24	New therapies for anaplastic thyroid cancer. Drugs of Today, 2018, 54, 695.	1.1	6
25	P26.02 A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results. Journal of Thoracic Oncology, 2021, 16, S1039-S1040.	1.1	6
26	Epidemiology and treatment trends for primary tracheal squamous cell carcinoma. Laryngoscope, 2020, 130, 405-412.	2.0	5
27	Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC. Npj Precision Oncology, 2021, 5, 91.	5.4	5
28	First-line Chemotherapy Responsiveness and Patterns of Metastatic Spread Identify Clinical Syndromes Present Within Advanced KRAS Mutant Nonâ€“Small-cell Lung Cancer With Different Prognostic Significance. Clinical Lung Cancer, 2018, 19, 531-543.	2.6	3
29	Cecal Volvulus as a Rare Complication of Osimertinib Dosed at 160 mg in Patients With EGFR-Mutant Non-small Cell Lung Cancer. Frontiers in Oncology, 2020, 10, 510.	2.8	3
30	Case Report: Significant Clinical Benefit From Pemetrexed-Based Therapy in ROS1- and ALK-rearranged Lung Cancer With Adenosquamous Histology. Frontiers in Oncology, 2021, 11, 788245.	2.8	3
31	CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusionsâ€”A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210).. Journal of Clinical Oncology, 2021, 39, TPS449-TPS449.	1.6	2
32	MO01.33 CRESTONE â€“ Clinical Study of REsponse to Seribantumab in Tumors with NEuregulin-1 (NRG1) Fusions â€“ A Phase 2 Study of the anti-HER3 mAb for Advanced or Metastatic Solid Tumors (NCT04383210). Journal of Thoracic Oncology, 2021, 16, S29-S30.	1.1	2
33	FP14.06 Multicenter Analysis of Mechanisms of Resistance to Osimertinib (O) in EGFR Mutated NSCLC: An ATOMIC Registry Study. Journal of Thoracic Oncology, 2021, 16, S229-S230.	1.1	2
34	Association of anticoagulant use with clinical outcomes from crizotinib in ALK <scp> â€ </scp> and ROS1 â€rearranged advanced nonâ€small cell lung cancers: A retrospective analysis of <scp>PROFILE</scp> 1001. Cancer Medicine, 2022, , .	2.8	2
35	G1T28, a CDK4/6 inhibitor, preserves T lymphocyte function from damage by cytotoxic chemotherapy. European Journal of Cancer, 2016, 69, S143-S144.	2.8	1
36	Deferring Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Non-Small Cell Lung Cancer: A Multi-Institutional Analysis. International Journal of Radiation Oncology Biology Physics, 2016, 96, S57-S58.	0.8	1

#	Article	IF	Citations
37	P1.07-002 G1T28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results. Journal of Thoracic Oncology, 2017, 12, S696.	1.1	1
38	Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.. Journal of Clinical Oncology, 2021, 39, 9124-9124.	1.6	1
39	Smad4 expression and chemosensitivity in non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, e20550-e20550.	1.6	1
40	The answer is skin deep: A case of intravascular large B cell lymphoma presenting as progressive paresis and bilateral abducens nerve palsy. Case Reports in Clinical Pathology, 2016, 3, .	0.0	0
41	PS01.68: Heterogeneous Clinical Syndromes Existing Within Patients with Stage IV KRAS Mutant Nonâ€“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2016, 11, S313.	1.1	0
42	MA02.01 ROS1 Gene Rearrangements Are Associated with an Exaggerated Risk of Peri-Diagnosis Thromboembolic Events. Journal of Thoracic Oncology, 2018, 13, S357-S358.	1.1	0
43	P1.01-78 The Incidence of Brain Metastases in ROS1-Rearranged Non-Small Cell Lung Cancer at Diagnosis and Following Progression on Crizotinib. Journal of Thoracic Oncology, 2018, 13, S492-S493.	1.1	0
44	Untapped potential: recognising CNS opportunities in early oncology drug development. Lancet Oncology, The, 2019, 20, 1620-1622.	10.7	0
45	Extending the Duration of Efficacy of Targeted Therapies with Radiation to Oligoprogressive Disease (OPD) in Oncogene-Driven Metastatic Non-Small Cell Lung Cancer (NSCLC). International Journal of Radiation Oncology Biology Physics, 2019, 105, S149.	0.8	0
46	P2.03-06 Detection of ctDNA and Correlation with Tumor Mutation Testing in Early Stage NSCLC. Journal of Thoracic Oncology, 2019, 14, S684.	1.1	0
47	P1.14-27 Duration of Targeted Therapy in Advanced NSCLC (aNSCLC) with Drivers Identified by Circulating Tumor DNA (ctDNA) Analysis. Journal of Thoracic Oncology, 2019, 14, S564.	1.1	0
48	P1.01-87 Osimertinib Acquired Resistance Mechanisms and Post-Progression Outcomes in Stage IV EGFR Positive Non-Small Lung Cancer. Journal of Thoracic Oncology, 2019, 14, S394.	1.1	0
49	P76.14 Time to First Progression in Patients with NSCLC with Brain Metastases Receiving 3rd Generation TKI alone vs TKI + Brain Radiation. Journal of Thoracic Oncology, 2021, 16, S591-S592.	1.1	0
50	Duration of pemetrexed maintenance therapy with or without pembrolizumab is associated with risk of renal toxicity in patients with metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2021, 39, e21205-e21205.	1.6	0
51	Abstract 1375: Activity of pemetrexed in patients with driver oncogene positive non-small cell lung cancer and squamous histology. , 2021, , .		0
52	The role of positron emission tomography fused with computed tomography (PET/CT) versus CT alone in detecting oligoprogressive disease (OPD) in oncogene-addicted non-small cell lung cancer (NSCLC) receiving tyrosine kinase inhibitor (TKI) therapy.. Journal of Clinical Oncology, 2017, 35, e20683-e20683.	1.6	0
53	Tucatinib. HER2 (ErbB2) inhibitor, Treatment of breast and colorectal cancer. Drugs of the Future, 2019, 44, 11.	0.1	0
54	Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.. Journal of Clinical Oncology, 2019, 37, 9090-9090.	1.6	0

#	Article	IF	Citations
55	NRG1 Fusion-Positive Lung Cancers: Clinicopathologic Profile and Treatment Outcomes from a Global Multicenter Registry. , 2019, , .		0
56	In Response to: â€œComparing Addition of Radiotherapy in EGFR- and ALK-Positive NSCLC With Brain Metastases: Are We Evaluating the Optimal Endpoint?â€• Journal of Thoracic Oncology, 2022, 17, e12-e14.	1.1	0
57	Adjuvant Osimertinib in EGFR-Mutant Early-Stage NSCLC: Does HRQoL Influence Decisions?. Clinical Cancer Research, 2022, , OF1-OF2.	7.0	0